KaloBios Pharmaceuticals Inc. , the company formerly majority owned by controversial biotech investor Martin Shkreli, said Friday it has filed its outstanding 10-Q and 10-K for 2015. The filings “mark an important step towards the achievement of one of the company’s key near-term goals of regaining compliance with periodic reporting requirements of the SEC and to seek relisting on a national securities exchange,” the company said in a statement. The company emerged from bankruptcy on June 30 with a new management team and new pricing strategy. It fired Shkreli from his role of CEO late last year, after he was arrested on charges of securities fraud relating to another company. KaloBios specializes in drugs to treat rare diseases. Shares, which trade over the counter, were not yet active in premarket trade.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News